QbD Costs Less
This article was originally published in The Gold Sheet
At the Sept. 24 joint PDA/FDA regulatory workshop discussion on the ICH Q8 guideline in Washington, which introduces the concept of design space, Moheb Nasr, director of the Office of New Drug Quality Assessment at CDER, said that "the more you understand [the drug product] at small-scale, the less you have to do at the commercial operation….I think you wind up reducing the costs in the long-run. The cost of QbD is much less than what people think." Nasr added that manufacturers who are confused about what to submit "when you're in the IND process for Phase 2, have a dialogue with the agency. We can provide free advice to you.
You may also be interested in...
DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker